Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Gholizadeh, Shima; Dolman, M. Emmy M.; Wieriks, Rebecca; Sparidans, Rolf W.; Hennink, Wim E.; Kok, Robbert J.

doi:10.1007/s11095-018-2373-x

Cited by 25 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is probable that, due to all these difficulties, nanoparticle functionalization with anti-glycan Abs will require further exploration. To our knowledge, the first experimental attempts to link anti-glycan antibodies to nanoparticle platforms have involved the anti-GD2 Abs or their fraction in the targeting and treatment of neuroblastoma [ 69 , 70 ]. As recently summarized by the Rodríguez-Nogales group, anti-GD2 Abs were efficiently conjugated with metallic, lipidic, and polymeric nanoparticles for tumor-specific targeting of neuroblastoma, with high potential to serve as a multifunctional therapeutic nanoplatform [ 69 ].…”

Section: Decorating Nanoparticles Surfaces With Tacas-binding Molementioning

confidence: 99%

Targeting the “Sweet Side” of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis

et al. 2021

View full text Add to dashboard Cite

Nanotechnology is in the spotlight of therapeutic innovation, with numerous advantages for tumor visualization and eradication. The end goal of the therapeutic use of nanoparticles, however, remains distant due to the limitations of nanoparticles to target cancer tissue. The functionalization of nanosystem surfaces with biological ligands is a major strategy for directing the actions of nanomaterials specifically to tumor cells. Cancer formation and metastasis are accompanied by profound alterations in protein glycosylation. Hence, the detection and targeting of aberrant glycans are of great value in cancer diagnosis and therapy. In this review, we provide a brief update on recent progress targeting aberrant glycosylation by functionalizing nanoparticles with glycan-binding molecules (with a special focus on lectins and anti-glycan antibodies) to improve the efficacy of nanoparticles in cancer targeting, diagnosis, and therapy and outline the challenges and limitations in implementing this approach. We envision that the combination of nanotechnological strategies and cancer-associated glycan targeting could remodel the field of cancer diagnosis and therapy, including immunotherapy.

show abstract

Section: Decorating Nanoparticles Surfaces With Tacas-binding Molementioning

confidence: 99%

Targeting the “Sweet Side” of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Overexpression of GD2 in different tumor types has been observed in different patterns. Targeting GD2 by high specificity and highaffinity monoclonal antibodies has become a strategy for NB diagnosis and treatment (Gholizadeh et al, 2018; 2.12 | Ornithine decarboxylase (ODC)…”

Section: Gd2mentioning

confidence: 99%

“…Overexpression of GD2 in different tumor types has been observed in different patterns. Targeting GD2 by high specificity and high‐affinity monoclonal antibodies has become a strategy for NB diagnosis and treatment (Gholizadeh et al, 2018; Pastorino et al, 2019; Rodriguez‐Nogales, Noguera, Patrick, & Blanco‐Prieto, 2019). 3F8 is an important murine monoclonal antibody (mAb) with high antitumor activity against NB by causing antibody‐directed cellular cytotoxicity (ADCC).…”

Section: Targets For Drug Delivery To Nbmentioning

confidence: 99%

“…Etoposide may cause some off‐target side effects such as myelosuppression, acute hypotension, nephrotoxicity, and activation of secondary leukemia in high‐risk patients (National Center for Biotechnology Information, 2018; Yavuz et al, 2018). GD2 is expressed on neural crest‐originated and peripheral nerve cancerous cells and it would be a good strategy to target this molecule by antibodies to deliver the drugs more effectively to the target (Gholizadeh et al, 2018). Coating liposomes with hydrophilic agents will decrease the total drug dose needed, by lowering cellular drug uptake in off‐target sites and decreasing the immune system evasion, resulting in a higher level of free drug available in blood circulation in comparison with the conventional drug delivery system.…”

Section: Nanocarriers Used In Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Neuroblastoma‐targeted nanoparticles and novel nanotechnology‐based treatment methods

Mobasheri

Rayzan

Shabani

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Neuroblastoma is a complicated pediatric tumor, originating from the neural crest, which is the most prevalent in adrenal glands, but may rarely be seen in some other tissues as well. Studies are focused on developing new strategies through novel chemo-and immuno-therapeutic drug targets. Different types of oncogenes such as MYCN, tumor suppressor genes such as p53, and some structural genes such as vascular endothelial growth factor are considered as targets for neuroblastoma therapy. The individual expression patterns in NB cells make them appropriate for this purpose. The combined effect of nano-drug delivery systems and specific drug targets will result in lower systemic side effects, prolonged therapeutic effects, and improvements in the pharmacokinetic properties of the drugs. Some of these novel drug delivery systems with a focus on liposomes as carriers are also discussed. In this review, genes and protein products that are beneficial as drug targets in the treatment of neuroblastoma have been discussed.

show abstract

“…Peptide Targeting. Peptide-based ligands engineered to NPs have been designed from the neuronal signaling pathways In vitro/in vivo Gholizadeh et al (2018) ALK, anaplastic lymphoma kinase; DOX, doxorubicin; GD2, disialoganglioside 2; PTX, pertussin; VEGF, vascular endothelial growth factor.…”

Section: Targeted Nanomedicines For Neuroblastomamentioning

confidence: 99%

Therapeutic Opportunities in Neuroblastoma Using Nanotechnology

Rodríguez-Nogales

Noguera

Couvreur

et al. 2019

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most common extracranial solid tumor preferentially occurring in preschoolers. Its characteristic aggressiveness and heterogeneous clinical behavior are especially visible in relapsed or refractory cases and hamper therapeutic success. Although the introduction of novel antitumor agents, such as dinutuximab, isotretinoin, irinotecan, or I-131-metaiodobenzylguanidine, has increased survival rates, the situation in high-risk NB remains dismal. Moreover, treatment is particularly aggressive in these patients, leading to short-and long-term toxicities. The extensive research performed using nanotechnology in recent decades has prompted its application as a therapeutic alternative to overcome some of the common limitations of conventional chemotherapy. Nevertheless, the therapeutic role of nanomedicine in pediatric tumors like NB is not fully elucidated, and to date, only albuminbound paclitaxel nanoparticles have reached clinic stages. In this review, we summarize the current therapeutic strategies for NB with special attention to the use of nanomedicine. We also highlight the preclinical studies on passive and active targeting nanodelivery of therapeutics in experimental NB models.

show abstract

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Cited by 25 publications

References 40 publications

Targeting the “Sweet Side” of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis

Targeting the “Sweet Side” of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis

Neuroblastoma‐targeted nanoparticles and novel nanotechnology‐based treatment methods

Therapeutic Opportunities in Neuroblastoma Using Nanotechnology

Contact Info

Product

Resources

About